Kiniksa Pharmaceuticals announces Phase 2/3 trial for KPL-387, targeting recurrent pericarditis, expected mid-2025. Data available in late 2026. Kiniksa Pharmaceuticals announced that it is set to ...
CG Oncology now plans to share topline data from the Phase 3, randomized, open-label PIVOT-006 registrational study in the first half of 2026. This expedited timeline is due to the rapid study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results